In the past decade, the therapeutic landscape of CLL has considerably improved, offering the possibility for patients with TP53 defects to benefit from targeted therapy with BcR pathway or bcl2 inhibitors (6–8). This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.